/NCEL

NCEL Stock - NewcelX Ltd.

Q: What is the analyst price target for NCEL?

Analyst price target information is not currently available for NCEL.

Q: What is NCEL's market cap?

Market capitalization information is not currently available for NCEL.

Healthcare|Biotechnology|NASDAQ

$2.60-4.06%

$0.11 (-4.06%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.86

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NCEL

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.57

52W High$33.70

52W Low$2.48

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-3,321	$-11,408	$-11,408	$-10,050	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-4,380,113	$-11,807,063	$-15,482,360	$-11,860,620	$-2,299,370
Net Income	$-1,980,810	$-12,172,029	$-16,495,680	$-11,946,078	$-2,861,435
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-26.30	$-3.20	$-8.40	$-8.10	$-5.90

Company Overview

NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.

Visit Website

Earnings History & Surprises

NCEL

Beat Rate

100%

Last 5 quarters

Avg Surprise

+97.2%

EPS vs Estimate

Beats / Misses

5/0

Last 12 quarters

Latest EPS

$-5.54

Q4 2025

EPS Surprise History

Q2 21

+95.0%

$-0.34vs$-6.80

Q3 21

No data

Q1 22

+96.4%

$-0.50vs$-13.80

Q4 22

No data

Q2 23

+97.5%

$-0.29vs$-12.00

Q2 23

+97.1%

$-0.20vs$-6.80

Q2 24

+100.0%

$-0.00vs$-8.40

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Oct 6, 2025	—	$-5.54	—	—
Q2 2025	May 16, 2025	—	—	—	—
Q4 2024	Oct 18, 2024	—	—	—	—
Q2 2024	May 15, 2024	$-8.40	$-0.00	+100.0%	✓ BEAT
Q2 2023	Jun 30, 2023	$-6.80	$-0.20	+97.1%	✓ BEAT
Q2 2023	May 5, 2023	$-12.00	$-0.29	+97.5%	✓ BEAT
Q4 2022	Oct 11, 2022	—	$-0.54	—	—
Q1 2022	Mar 24, 2022	$-13.80	$-0.50	+96.4%	✓ BEAT
Q3 2021	Sep 28, 2021	—	$-0.42	—	—
Q2 2021	May 14, 2021	$-6.80	$-0.34	+95.0%	✓ BEAT
Q2 2020	Jun 30, 2020	—	$-0.11	—	—
Q4 2019	Dec 31, 2019	—	$-0.18	—	—
Q2 2019	Jun 30, 2019	—	$-0.31	—	—
Q4 2018	Dec 31, 2018	—	$-19.32	—	—
Q2 2018	Jun 30, 2018	—	$-13.57	—	—
Q2 2017	Jun 30, 2017	—	$-0.16	—	—